Health Condition 1: H578- Other specified disorders of eye and adnexa
Conditions
Interventions
Intervention1: Octreotide Therapy: Somatostatin Receptor PET/CT will be done to assess SSTR expression. One of the two groups with positive SSTR PET/CT will be given Octreotide LAR in addition to stan
Sponsors
Research Section AIIMS New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: a) patients with Graves orbitopathy with failed first line of intravenous steroid therapy, before starting second line b) age more than 18 years c) Clinical activity score more than 3 d) with contraindication for other immunosuppressive therapy
Exclusion criteria
Exclusion criteria: 1) Pregnant and lactating women. 2) Patient on another immunosuppressive therapy 3) patients urgently needing surgical decompression 4) Impending Dysthroid optic neuropathy (DON) 5) Patients in whom urgent second line therapy is required
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)To assess somatostatin receptor expression in orbital soft tissue with Ga 68 DOTANOC PET/CT 2) To evaluate response to both steroid and steroid plus octreotide therapy in the two groups of patients with somatostatin receptor expressing Graves orbitopathy by CAS, EUGOGO scoring, Exophthalmometry, field charting, acuity testing, colour vision testing and achievement of cosmesis at 3 and 6 month intervals after therapy Timepoint: Patient Recruitment 0-24 months SSTR PET/CT 0-24 MONTHS Octreotide Therapy 0-24months Follow up 0-30 months Data Analysis 30-36 months | — |
Secondary
| Measure | Time frame |
|---|---|
| not applicableTimepoint: not applicable | — |
Countries
India
Contacts
Public ContactDR NISHIKANT AVINASH DAMLE
ALL INDIA INSTITUTE OF MEDICAL SCIENCES
Outcome results
None listed